Literature DB >> 17344918

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

J Corre1, K Mahtouk, M Attal, M Gadelorge, A Huynh, S Fleury-Cappellesso, C Danho, P Laharrague, B Klein, T Rème, P Bourin.   

Abstract

Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well. To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy age-matched subjects. Gene expression profile independently classified the BMMSCs of these individuals in a normal and in an MM group. MGUS BMMSCs were interspersed between these two groups. Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk. Known soluble factors implicated in MM pathophysiologic features (i.e. IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth. In particular, GDF15 was found to induce dose-dependent growth of MOLP-6, a stromal cell-dependent myeloma cell line. Functionally, MM BMMSCs induced an overgrowth of MOLP-6, and their capacity to differentiate into an osteoblastic lineage was impaired. Thus, MM BMMSCs are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344918      PMCID: PMC2346535          DOI: 10.1038/sj.leu.2404621

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

1.  Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.

Authors:  T Vincent; M Jourdan; M S Sy; B Klein; N Mechti
Journal:  J Biol Chem       Date:  2001-01-29       Impact factor: 5.157

Review 2.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

Authors:  D Gupta; S P Treon; Y Shima; T Hideshima; K Podar; Y T Tai; B Lin; S Lentzsch; F E Davies; D Chauhan; R L Schlossman; P Richardson; P Ralph; L Wu; F Payvandi; G Muller; D I Stirling; K C Anderson
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

4.  The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women.

Authors:  A G Moore; D A Brown; W D Fairlie; A R Bauskin; P K Brown; M L Munier; P K Russell; L A Salamonsen; E M Wallace; S N Breit
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

5.  Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases.

Authors:  A Grey; T Banovic; D Naot; B Hill; K Callon; I Reid; J Cornish
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

6.  Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

Authors:  T Michigami; N Shimizu; P J Williams; M Niewolna; S L Dallas; G R Mundy; T Yoneda
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

7.  Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior.

Authors:  J J Contos; N Fukushima; J A Weiner; D Kaushal; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.

Authors:  S R Wallace; M M Oken; K L Lunetta; A Panoskaltsis-Mortari; A M Masellis
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

9.  Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.

Authors:  Anthony Calabro; Martin M Oken; Vincent C Hascall; Anna M Masellis
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

10.  Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis.

Authors:  Trevor Starnes; Hal E Broxmeyer; Michael J Robertson; Robert Hromas
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

View more
  119 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 3.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

4.  Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.

Authors:  Sabine Pfeifer; Martin Schreder; Arnold Bolomsky; Sebastian Graffi; Dietmar Fuchs; Surinder S Sahota; Heinz Ludwig; Niklas Zojer
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

Review 5.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

6.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 8.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

9.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Authors:  Caroline Bret; Dirk Hose; Thierry Reme; Anne-Catherine Sprynski; Karène Mahtouk; Jean-François Schved; Philippe Quittet; Jean-François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.